Schering-Plough transfers products in European market
Kenilworth, N.J. -- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
Kenilworth, N.J.
-- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
The transfers were requested by the European Commission as part of an October 2007 clearance of the acquisition of Oraganon BioSciences N.V. by Pfizer.
Products transferred to Pfizer in the European market include products from Schering-Plough's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory companion animal/insulin and companion animal/euthanasia and rabies vaccine franchises, according to Schering-Plough.
Schering-Plough still will be able to market those items outside of the European market, according to the company.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More
